| DC9685 |
Evatanepag (CP-533536)
Featured
|
Evatanepag (CP-533536) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM. |
|
| DC9073 |
Famotidine |
Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. |
|
| DC8912 |
Fesoterodine fumarate
Featured
|
Fesoterodine Fumarate is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. |
|
| DC11278 |
Fevipiprant
Featured
|
Fevipiprant(QAW039) is a selective, potent, reversible competitive CRTh2 antagonist with an in vitro dissociation constant KD value of 1.1nM at the CRTh2 receptor and an IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change. |
|
| DC9175 |
Fexofenadine Hydrochloride
Featured
|
Fexofenadine is a third-generation antihistamine pharmaceutical drug used in the treatment of allergy symptoms, such as hay fever, nasal congestion, and urticaria. |
|
| DC8936 |
Fingolimod |
Fingolimod(FTY720 free base) is a S1P antagonist with IC50 of 0.033 nM. |
|
| DC9164 |
Flupenthixol dihydrochloride
Featured
|
Flupenthixol dihydrochloride is a typical antipsychotic of the thioxanthene class that acts as an antagonist at dopamine D2 receptors (Ki = 0.38 nM) and an inverse agonist at serotonin 5-HT2A receptors (Ki = 7 nM).1 It has also been identified as an inhib |
|
| DC7016 |
JNJ40411813
Featured
|
For the detailed information of JNJ40411813, the solubility of JNJ40411813 in water, the solubility of JNJ40411813 in DMSO, the solubility of JNJ40411813 in PBS buffer, the animal experiment (test) of JNJ40411813, the cell expriment (test) of JNJ40411813, the in vivo, in vitro and clinical trial test of JNJ40411813, the EC50, IC50,and Affinity of JNJ40411813, Please contact DC Chemicals.. |
|
| DCAPI1596 |
Metroprolol succinate |
For the detailed information of Metroprolol succinate, the solubility of Metroprolol succinate in water, the solubility of Metroprolol succinate in DMSO, the solubility of Metroprolol succinate in PBS buffer, the animal experiment (test) of Metroprolol succinate, the cell expriment (test) of Metroprolol succinate, the in vivo, in vitro and clinical trial test of Metroprolol succinate, the EC50, IC50,and Affinity of Metroprolol succinate, Please contact DC Chemicals.. |
|
| DC9333 |
Formoterol (Fumarate)
Featured
|
Formoterol fumarate(Foradil) is a potent, selective and long-acting β2-adrenoceptor agonist.
|
|
| DC4201 |
Fosaprepitant dimeglumine
Featured
|
Fosaprepitant (MK-0517, L-758,298) is a water-soluble phosphoryl prodrug for Aprepitant which is a NK1 antagonist. |
|
| DC10814 |
G-15
Featured
|
G-15 is a cell-permeable non-steroidal antagonist of GPER (Ki = 20 nM). |
|
| DC10816 |
G-36
Featured
|
G-36 is a cell-permeable non-steroidal antagonist of GPER, inhibiting activation by either 17β-estradiol or the GPER-selective agonist G-1(IC50 = 112 and 165 nM, respectively). |
|
| DC11122 |
GAT-100 |
GAT-100 (GAT100) is a potent, selective CB1R negative allosteric modulator (NAM) with cAMP EC50 and β-arr EC50 of 174 nM and 2.1 nM, does not exhibit inverse agonism. |
|
| DC11119 |
GAT-211 |
GAT-211 (GAT211) is a selective cannabinoid 1 receptor (CB1R) positive allosteric modulator with pKb of 7.26, Arrestin2 EC50 of 775 nM. |
|
| DC11741 |
GB-110 |
GB-110 is a potent, non-peptidic agonist of PAR2 that selectively induces PAR2-mediated intracellular Ca(2+) release in HT29 cells with EC50 of 0.28 uM. |
|
| DC11740 |
GB-88 |
GB-88 is a selective, orally available PAR2 antagonist that inhibits PAR2 activated Ca(2+) release with IC50 of 2 uM. |
|
| DC12342 |
Gemilukast (ONO-6950) |
Gemilukast is an orally active and potent dual cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2) antagonist, with IC50s of 1.7, 25 nM for human CysLT1 and CysLT2, respectively. |
|
| DC11246 |
Ghrelin agonist HM01
Featured
|
Ghrelin agonist HM01 is a novel potent, orally available ghrelin (GHS-R) agonist with Ki of 1.42 nM (human GHS-R1a), induces potent activation of intracellular calcium signaling with EC50 of 1.25 nM. |
|
| DC10003 |
PF-06291874（glucagon receptor antagonists-4）
Featured
|
glucagon receptor antagonists-4 is a highly potent glucagon receptor antagonist. |
|
| DC8779 |
Glycopyrrolate
Featured
|
Glycopyrrolate(Glycopyrronium Br) is a muscarinic competitive antagonist used as an antispasmodic. |
|
| DC8593 |
GPR120 Compound A
Featured
|
GPR120 compound A is an orally available, high-affinity agonist of GPR120 (EC50 = ~0.35 µm) that demonstrates potent selectivity over another lipid-sensing G-protein, GPR40 (FFAR1). |
|
| DC8206 |
GPR39-C3
Featured
|
GPR39-C3 is the first potent, selective and orally bioavailable GPR39 agonist with an EC50 ~0.8 nM for human GPR39 and ~0.4 nM for rodent GPR39. |
|
| DC11143 |
GPR40 AgoPAM AP5 |
GPR40 AgoPAM AP5 is a potent, selective GPR40 AgoPAM (full agonist with positive allosteric modulation) with hIP1 EC50 of 0.8 nM, high selectivity over the GPR120 receptor (EC50>30 uM). |
|
| DC9299 |
GRA Ex-25
Featured
|
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model at 10 and 30 mpk. |
|
| DC9080 |
Granisetron HCl |
Granisetron Hcl(BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy. |
|
| DC7422 |
GSK1292263
Featured
|
GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. |
|
| DC8577 |
FFA4 (GPR120) agonist GSK137647A
Featured
|
GSK-137647 is a potent and selective FFA4 (GPR120) agonist (pEC50 values are 6.3, 6.2 and 6.1 at the human, mouse and rat receptor, respectively). Exhibits ≥100-fold selectivity against a panel of 61 targets including FFA1, FFA2 and FFA3. |
|
| DC9705 |
GSK163090
Featured
|
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for 5-HT1A/B/D, and dopamine D2/D3, respectively. |
|
| DC10102 |
GSK189254A
Featured
|
GSK189254A (GSK189254) is a novel, potent and selective histamine H3 receptor antagonist with pKi values of 9.59-9.90 and 8.51-9.17 for human and rat H3, respectively. |
|
